Gout

(redirected from chronic gout)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.

GOUT, med. jur. contracts. An inflammation of the fibrous and ligamentous parts of the joints.
     2. In cases of insurance on lives, when there is warranty of health, it seems that a man subject to the gout, is a life capable of being, insured, if he has no sickness at the time to make it an unequal contract. 2 Park, Ins. 583.

Mentioned in ?
References in periodicals archive ?
Chronic gout: epidemiology, disease progression, treatment and disease burden.
These parallel trials "have documented sustained [uric acid] reductions and significant clinical improvement in a substantial proportion of patients with chronic gout and refractoriness to, or intolerance of, conventional urate-lowering therapy," the investigators wrote.
Progressive reduction in tophus burden wtih pegloticase therapy in patients with chronic gout refractory to conventional therapy.
It is the only FDA-approved product specifically indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.
It won't help in diagnosing acute gout, and should only be used to evaluate bone and joint erosions in chronic gout.
Former landlord Mark, who lives in Greetland, needed the transplant after being affected by chronic gout.
Pegloticase, a recombinant formulation of porcine uricase, has been approved for the treatment of chronic gout in adults who are refractory to conventional treatments.
If the patient has more than two attacks per year or one attack and also suffers from Gout, has chronic gout, chronic kidney disease.
Horizon Pharma plc, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that four new data analyses evaluating the use of KRYSTEXXA (pegloticase) in patients with refractory chronic gout will be presented at the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid on June 15, 2017.
"In patients with chronic gout treated with a xanthine oxidase inhibitor (allopurinol or febuxostat) to lower the serum urate" to recommended target levels below 6.0 mg/dL, "the small elevation in serum urate is unlikely to negate the clinical efficacy of these drugs when dosing is optimized," Dr.
Market growth can be attributed to the introduction of major urate-lowering agents, approval of effective biologics, and increasing number of patients suffering from chronic gout.
Treatment of gout consists in the early correction of asymptomatic hyperuricemias, the treatment of the acute gout attack, the prevention of new attacks and the prevention of chronic gout. The nonpharmacologic measures consist of putting at rest the inflicted joint during the acute attack and taking dietary choices.

Full browser ?